Rheumatic Disease in the Elderly: Rheumatoid Arthritis

Rheumatic Disease Clinics of North America

Volumn 33, Issue 1, 2007, Pages 57-70

  Tutuncu, Zuhre ^a   Kavanaugh, Arthur ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; AZATHIOPRINE; CHONDROITIN SULFATE; COLCHICINE; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GLUCOSAMINE; HYALURONIC ACID; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PLACEBO; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; SALAZOSULFAPYRIDINE; STEROID;

ADD ON THERAPY; ANTIBODY PRODUCTION; BONE MARROW SUPPRESSION; CALCIUM PYROPHOSPHATE DEPOSITION DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CHILL; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CYTOPENIA; DEMYELINATING DISEASE; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DIZZINESS; FEVER; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL IRRITATION; GINGIVA HYPERTROPHY; GOUT; HEADACHE; HIRSUTISM; HUMAN; HYPERTENSION; INFECTION; INJECTION SITE REACTION; KIDNEY FAILURE; LIVER FUNCTION TEST; LUPUS LIKE SYNDROME; MOUTH ULCER; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; OSTEOARTHRITIS; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; PRURITUS; PSEUDOGOUT; RASH; REVIEW; RHEUMATIC POLYMYALGIA; RHEUMATOID ARTHRITIS; SIDE EFFECT; SKIN DISCOLORATION; TREMOR;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; HUMANS; OSTEOARTHRITIS; POLYMYALGIA RHEUMATICA; PROGNOSIS;

EID: 33947183120     PISSN: 0889857X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rdc.2006.12.006     Document Type: Review

References (58)

1. Rasch E.K., Hirsch R., Paulose-Ram R., et al. Prevalence of rheumatoid arthritis in persons 60 years of age and older in the United States. Effect of different methods of case classification. Arthritis Rheum 48 (2003) 917-926
2. van Schaardenburg D., and Breedweld F.C. Elderly-onset rheumatoid arthritis. Semin Arthritis Rheum 23 6 (1994) 367-378
3. Nesher G., and Moore T.L. Rheumatoid arthritis in the aged. Incidence and optimal management. Drugs Aging 3 (1993) 487-501
4. Kavanaugh A.F. Rheumatoid arthritis in the elderly: is it a different disease?. Am J Med 103 6A (1997) 40S-48S
5. Sangha O. Epidemiology of rheumatic diseases. Rheumatology (Oxford) 39 Suppl 2 (2000) 3-12
6. Dugowson C.E., Nelson J.L., and Koepsell T.D. Evaluation of the 1987 revised criteria for rheumatoid arthritis in a cohort of newly diagnosed female patients. Arthritis Rheum 33 (1990) 1042-1046
7. Pincus T., and Callahan L.F. How many types of patients meet classification criteria for rheumatoid arthritis?. J Rheumatol 21 (1994) 1385-1389
8. Arnett F.C., Edworthy S.M., Bloch D.A., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31 (1988) 315-324
9. Feldman M., Brennan F.M., and Maini R.N. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 43 (1996) 28-38
10. Deal C.L., Meenan R.D., Goldenberg D.L., et al. The clinical features of elderly-onset rheumatoid arthritis. Arthritis Rheum 28 (1985) 987-994
11. Ferraccioli G.F., Cavelieri F., Mercadanti M., et al. Clinical features, scintiscan characteristics and X-ray progression of late onset rheumatoid arthritis. Clin Exp Rheumatol 2 (1984) 157-161
12. Glennas A., Tore K.K., Oddvar A., et al. Recent onset arthritis in the elderly: a five year longitudinal observational study. J Rheumatol 27 (2000) 101-108
13. van der Heijde D.M., van Riel P.L., van Leeuwen M.A., et al. Older versus younger onset rheumatoid arthritis: results at onset and after 2 years of a prospective follow-up study of early rheumatoid arthritis. J Rheumatol 18 (1991) 1285-1289
14. Palosuo T., Tilvis R., Strandberg T., et al. Filaggrin related antibodies among the aged. Ann Rheum Dis 62 (2003) 261-263
15. Oka M., and Kytila J. Rheumatoid arthritis with the onset in old age. Acta Rheumatol Scand 6 (1957) 280-283
16. Terkeltaub R., Esdaile J., Decary F., et al. A clinical study of older age rheumatoid arthritis with comparison to a younger onset group. J Rheumatol 10 (1983) 418-424
17. Corrigam A.B., Robinson R.G., Terenty T.R., et al. Benign rheumatoid arthritis of the aged. BMJ 1 (1974) 444-446
18. van Schaardenburg D., Hazes J.M.W., de Boer A., et al. Outcome of rheumatoid arthritis in relation to age and rheumatoid factor at diagnosis. J Rheumatol 20 (1993) 45-52
19. Wagner U., Kaltenhauser S., Sauer S., et al. HLA markers and prediction of clinical course and outcome in rheumatoid arthritis. Arthritis Rheum 40 2 (1997) 341-351
20. Stummvoll GH, Aringer M, Machold KP, et al. Cancer polyarthrtis resembling rheumatoid arthritis as a first sign of hidden neoplasms, report of two cases and review of the literature. Scand J Rheumatol 2001;30(1):40-44.
21. Reilly P.A. The differential diagnosis of generalized pain. Baillieres Best Pract Res Clin Rheumatol 13 3 (1999) 391-401
22. Bijlsma J.W.J. Analgesia and the patient with osteoarthritis. Am J Ther 9 (2002) 189-197
23. Rahme E, Marantette MA, Kong SX, et al. Use of NSAIDs, COX-2 inhibitors, and acetaminophen and associated coprescriptions of gastroprotective agents in an elderly population. Arthritis Rheumatol 2002;47(6):595-02.
24. Whelton A., White W.B., Bello A.E., et al. Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or = 65 years of age with systemic hypertension and osteoarthritis. Am J Cardiol 90 9 (2002) 959-963
25. Bombardier C., Laine L., Reicin A., et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 343 (2000) 1520-1528
26. Alsalameh S., Burian M., et al. Review article: the pharmaceutical properties and clinical use of valdecoxib, a new cyclo-oxygenase-2-selective inhibitor. Aliment Phamacol Ther 17 (2003) 489-501
27. Healey L.A., and Sheets P.K. The relation of polymyalgia rheumatica to rheumatoid arthritis. J Rheumatol 15 (1988) 750-752
28. Lockie L.M., Gomez E., and Smith D.M. Low dose adrenocorticosteroids in the management of elderly patients with rheumatoid arthrtitis. Semin Arthritis Rheum 12 (1983) 373-381
29. van Schaardenburg D., Valkeme R., Dijkmans B.A.C., et al. Prednisone for elderly-onset heumatoid arthritis: efficacy and bone mass at one year. Arthritis Rheum 36 (1993) S269
30. Weinblatt M.E., Weisman R.F., Holdworth D.E., et al. Long-term prospective study of methotrexate in the treatment of rheumatoid arthritis. Arthritis Rheum 35 (1992) 721-730
31. Kremer J.M., Genovese M.C., Cannon G.W., et al. Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. Ann Intern Med 137 (2002) 726-733
32. O'Dell J.R., Haire C.E., and Erikson N. Treatment of rheumatoid arthritis with methotrexate sulfasalazine and hydroxychloroquine alone, or a combination of all three medications. N Engl J Med 334 (1996) 1287-1291
33. Pincus T., Marcum S.B., Callahan L.F., et al. Long term drug therapy for rheumatoid arthritis in seven rheumatology private practices. Second line drugs and prednisone. J Rheumatol 19 (1992) 1885-1894
34. Wolfe F., Hawley D.J., and Cathey M.A. Termination of slow acting anti-rheumatic therapy in rheumatoid arthritis: a 14 year prospective evaluation of 1017 consecutive starts. J Rheumatol 17 (1990) 994-1002
35. Maini R., St Clair E.W., Breedweld F., et al. Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase III trial. Lancet 354 (1999) 1932-1939
36. Moreland L.W., Baumgartner S.W., Schiff M.H., et al. Treatment of rheumatoid arthritis with a recombinant human tumour necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 337 (1997) 141-147
37. Weisman M.H., Moreland L.W., Furst D.E., et al. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. Clin Ther 25 6 (2003) 1700-1721
38. Lipsky P.E., Desiree M.F.M., van der H., et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 343 (2000) 1594-1602
39. Genovese M.C., Bathon J.M., Martin R., et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two year radiographic and clinical outcomes. Arthritis Rheum 46 (2002) 1443-1450
40. Keystone E., Kavanaugh A., Sharp J., et al. Adalimumab (D2E7), a fully human anti-TNFα monoclonal antibody, inhibits the progression of structural damage in patients with active rheumatoid arthritis despite concomitant methotrexate therapy. Arthritis Rheum 46 Suppl 9 (2002) S205 [abstract 468]
41. Fleischman R.M., Baumgartner S.W., Tindall E.A., et al. Response to etanercept (enbrel) in elderly patients with rheumatoid arthritis: a retrospective analysis of clinical trials. J Rheumatol 30 4 (2003) 691-696
42. Bresnihan B., Alvaro-Garcia J.M., Cobby M., et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 41 (1998) 2196-2204
43. Kremer J.M., Westhovens R., Leon M., et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 20 (2003) 1907-1915
44. Kremer J.M., Genant H.K., Moreland L.W., et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med 144 12 (2006) 865-876
45. Edwards J.C.W., and Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology 40 (2001) 205-211
46. Leonardo M.J., Edwards J.C.W., and Cambridge G. Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum Dis 61 (2002) 883-888
47. Edwards J.C.W., Szczepanski L., Szechinski J., et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350 (2004) 2572-2581
48. Tutuncu ZN, Kavanaugh A, Reed G, et al. Older onset rheumatoid arthritis patients receive biologic therapies less frequently than younger patients despite similar disease activity and severity: analysis from the CORRONA Database. Arthritis Rheum, in press [abstract].
49. Michet C.J., Evans J.M., Fleming K.C., et al. Common rheumatologic diseases in elderly patients. Mayo Clin Proc 70 (1995) 1205-1214
50. Derfus B.A., Kurian J.B., Butler J.J., et al. The high prevalence of pathologic calcium crystals in pre-operative knees. J Rheumatol 29 3 (2002) 570-574
51. Lawrence R.C., Hochberg M.D., et al. Estimates of the prevalence of selected arthritic and musculoskeletal diseases in the United States. J Reumatol 16 (1989) 427-441
52. Cobb K.L., Mendez E.A., and Espinoza L.R. Gouty arthritis mimicking rheumatoid arthritis. J Clin Rheumatol 4 (1998) 225
53. Peyron J.G. Epidemiologic and etiologic approach to osteoarthritis. Semin Arthritis Rheum 8 (1979) 288-306
54. Goldring M.B. The role of chondrocyte in osteoarthritis. Arthritis Rheum 43 (2000) 1916-1926
55. Dodge G.R., and Jimenez S.A. Glucosamine sulfate modulates the levels of aggrecan and matrix metalloproteinase-3 synthesized by cultured human osteoarthritis articular chondrocytes. Osteoarthritis Cartilage 6 (2003) 424-432
56. Clegg D.O., Reda D.J., Harris C.L., et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med 354 8 (2006) 795-808
57. Listrat V, Ayral X, Francesca P, et al. Arthroscopic evaluation of potential structure modifying activity of hyaluronan (Hyalgan) in osteoarthritis of the knee. Osteoarthritis Cartilage 1997;5:153-60.
58. Studenski S.A. Rheumatology, geriatrics, and a way forward. J Am Geriatr Soc 50 (2002) 1737-1738